How does relapse differ from progressive disease in multiple myeloma?

How Relapse Differs from Progressive Disease in Multiple Myeloma

Relapse and progressive disease are distinct clinical entities in multiple myeloma that differ fundamentally in their context and definition: relapse occurs in patients who previously achieved a response (at least minimal response) and then experience disease worsening, while progressive disease refers to the specific biochemical and clinical criteria used to define worsening disease in any patient, regardless of prior response status. 1

Key Conceptual Differences

Progressive Disease (PD)

Progressive disease is a measurement-based definition used to quantify disease worsening through specific laboratory and imaging criteria 1:

• 25% increase from lowest response value in M-protein (absolute increase ≥0.5 g/dL)
• For high M-protein (≥5 g/dL), an absolute increase of ≥1 g/dL suffices
• 25% increase in urine M-protein (absolute increase ≥200 mg/24h)
• ≥10% absolute increase in bone marrow plasma cells
• Appearance of new lesions or ≥50% increase in size of existing plasmacytomas/bone lesions
• Development of hypercalcemia (>11.5 mg/dL) attributable to myeloma

Progressive disease criteria apply to all patients at any treatment stage and are used to calculate time-to-progression and progression-free survival in clinical trials 1.

Relapse

Relapse is a clinical context that specifically describes patients who:

1. Previously achieved at least a minimal response to therapy
2. Subsequently meet criteria for progressive disease OR
3. Develop clinical symptoms requiring treatment intervention

Critical distinction: You cannot have "relapse" without first having achieved a response 2.

Types of Relapse

Biochemical Relapse

• Meets progressive disease criteria based on laboratory parameters alone
• No end-organ damage or symptoms present
• Patient remains asymptomatic
• Represents 60% of relapses 3

Clinical Relapse

Clinical relapse indicates symptomatic disease requiring treatment 1:

• Development of CRAB features (hypercalcemia, renal failure, anemia, bone lesions)
• New soft tissue plasmacytomas or bone lesions
• ≥50% increase in measurable lesion size (≥1 cm absolute increase)
• Hemoglobin decrease ≥2 g/dL
• Serum creatinine rise ≥2 mg/dL
• Hyperviscosity from paraprotein

Important caveat: Clinical relapse is not used to calculate time-to-progression or progression-free survival in trials but guides real-world treatment decisions 1.

Relapse from Complete Response

Has more stringent criteria 1:

• Reappearance of M-protein by immunofixation or electrophoresis
• Development of ≥5% plasma cells in bone marrow (versus ≥10% for other relapse categories)
• Any sign of progression (new plasmacytoma, lytic lesion, hypercalcemia)

Clinical Implications

Timing of Treatment Initiation

Patients with biochemical relapse have significantly better outcomes than those with clinical relapse 3:

• Median time to next treatment: 17.0 vs 9.6 months (p<0.001)
• Median overall survival from first relapse: 59.4 vs 26.2 months (p<0.001)

This suggests initiating therapy at biochemical progression prevents end-organ damage and improves survival 3, 4.

Predictors of Clinical vs Biochemical Relapse

Risk factors for developing clinical (symptomatic) relapse 3:

• Male sex (OR 1.49)
• Plasma cell labeling index ≥2% (OR 1.58)
• Extramedullary disease at diagnosis (OR 1.84)
• Protective factor: Achieving VGPR or better reduces clinical relapse risk (OR 0.62)

Common Pitfalls to Avoid

1. Don't confuse the terms: Progressive disease is a measurement tool; relapse is a clinical scenario requiring prior response
2. All relapses require two consecutive assessments before classification, except for MRD assessment 1
3. For clinical trial endpoints, patients in complete response must meet progressive disease criteria (not just clinical relapse criteria) for calculating progression-free survival 1
4. The specific CRAB symptom present at diagnosis predicts similar CRAB symptoms at relapse 3

Practical Algorithm

When evaluating disease worsening:

1. Did the patient previously achieve at least minimal response?

   • No → This is primary refractory disease, not relapse
   • Yes → Proceed to step 2

2. Does the patient meet progressive disease criteria?

   • Check M-protein, bone marrow plasma cells, imaging
   • Requires 25% increase from nadir with specified absolute increases

3. Are symptoms or end-organ damage present?

   • No → Biochemical relapse; consider early treatment initiation
   • Yes → Clinical relapse; treatment indicated

4. What was the prior response depth?

   • Complete response → Use 5% plasma cell cutoff
   • Less than complete response → Use 10% plasma cell cutoff

The distinction matters because biochemical relapse allows earlier intervention before irreversible organ damage occurs, translating to superior survival outcomes 3, 4.